Abstract

IntroductionCell-free deoxyribonucleic acid DNA (cf-DNA) in urine is promising due to the advantage of urine as an easily obtained and non-invasive sample source over tissue and blood. In clinical practice, it is important to identify non-invasive biomarkers of chronic kidney disease (CKD) in monitoring and surveillance of disease progression. Information is limited, however, regarding the relationship between urine and plasma cf-DNA and the renal outcome in CKD patients.MethodsOne hundred and thirty-one CKD patients were enrolled between January 2016 and September 2018. Baseline urine and plasma cell-free mitochondrial DNA (cf-mtDNA) and cell-free nuclear DNA (cf-nDNA) were isolated using quantitative real-time PCR. Estimated glomerular filtration rate (eGFR) measurement was performed at baseline and 6-month follow-up. Favorable renal outcome was defined as eGFR at 6 months minus baseline eGFR> = 0. Receiver operator characteristics (ROC) curve analysis was performed to assess different samples of cf-DNA to predict favorable renal outcomes at 6 months. A multivariate linear regression model was used to evaluate independent associations between possible predictors and different samples of cf-DNA.ResultsPatients with an advanced stage of CKD has significantly low plasma cf-nDNA and high plasma neutrophil gelatinase-associated lipocalin (NGAL) levels. Low urine cf-mtDNA, cf-nDNA levels and low plasma NGAL were significantly correlated with favorable renal outcomes at 6 months. The urine albumin-creatinine ratio (ACR) or urine protein-creatinine ratio (PCR) level is a robust predictor of cf-mtDNA and cf-nDNA in CKD patients. Baseline urine levels of cf-mtDNA and cf-nDNA could predict renal outcomes at 6 months.ConclusionsUrinary cf-mtDNA and cf-nDNA may provide novel prognostic biomarkers for renal outcome in CKD patients. The levels of plasma cf-nDNA and plasma NGAL are significantly correlated with the severity of CKD.

Highlights

  • Cell-free deoxyribonucleic acid DNA in urine is promising due to the advantage of urine as an obtained and non-invasive sample source over tissue and blood

  • To clarify the clinical application of cf-mtDNA and cell-free nuclear DNA (cf-nDNA) in chronic kidney disease (CKD), we studied the correlation between cf-mtDNA and cf-nDNA, both urine and plasma, and the stage of CKD or prognosis of renal outcomes

  • To the best of our knowledge, this study is the first to show the clinical significant correlation between urine cf-mtDNA, urine cf-nDNA and divergent renal outcome at 6 months. We propose that both urine protein-creatinine ratio (PCR) and albumin-creatinine ratio (ACR) could significantly predict urinary cf-nDNA and cfmtDNA levels

Read more

Summary

Introduction

Cell-free deoxyribonucleic acid DNA (cf-DNA) in urine is promising due to the advantage of urine as an obtained and non-invasive sample source over tissue and blood. It is important to identify non-invasive biomarkers of chronic kidney disease (CKD) in monitoring and surveillance of disease progression. Chronic kidney disease (CKD) is a global public health problem affecting up to 10% of the population worldwide [1], guidelines for the clinical staging of CKD have been established [2]. Proteinuria, caused by a primary insult to the kidney, induces oxidative stress in renal tubular cells and causes mitochondrial dysfunction [7, 8], which leads to cellular damage by. By the experimental models of CKD, preventing mitochondrial dysfunction inhibits renal tubular cell EMT and renal fibrosis [13]. Only a relatively small number of translational studies have shown the clinical relevance of these mechanisms between renal diseases and mitochondrial dysfunction in humans [6, 14, 15]

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.